Chi-Med gets U.S. fast-track for tumor treatment drug surufatinib

China’s biotechnology industry has emerged rapidly in recent years and Hutchison China MediTech Limited (Chi-Med) plans to file for an IPO listing in Hong Kong at some point in the future, says Christian Hogg, executive director and CEO of Chi-Med.

02:54

Fri, Jun 5 20203:43 AM EST